Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | MTOR | P42345 | 8/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196671 | 0.95 | ATR (0.57) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4207554 | 0.92 | ATR (0.53) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL3929968 | 0.89 | ATR (0.55) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4208562 | 0.88 | PIK3CA (0.53) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4208901 | 0.88 | ATR (0.70) | ATRPIK3CAMTORPIK3CD | |
| SCHEMBL4198258 | 0.87 | ATR (0.56) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4198492 | 0.86 | ATR (0.55) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4198533 | 0.86 | PIK3CA (0.50) | ATRPIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL3929318 | 0.85 | ATR (0.66) | ATRPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL3928177 | 0.85 | ATR (0.66) | ATRPIK3CAMTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | ATR 1185/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.